Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03975309 · ClinicalTrials.gov registry record

DHS MIND Metabolomics

A clinical trial of Diabetes, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
417
Enrollment target
1
Study location

NCT03975309 is a study of Diabetes that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 417 participants, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03975309, a study of Diabetes, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
417 participants
Enrollment target
1
Study location

Study Summary

The study team will evaluate whether metabolomic signatures of neurocognitive decline trajectories are exacerbated by the presence of type 2 diabetes mellitus (T2D) and whether these signatures contribute in part, to ethnic disparities in cognitive decline between European Americans and African Americans with T2D.

Conditions Studied

Study Locations (1)

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Trial Details

FieldValue
Enrollment Target 417 participants
Start Date 2019-09-09
Est. Completion 2023-05-23

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT03975309

The ClinicalTrials.gov registry entry for NCT03975309 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 417 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (86% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 0 interventions.

NCT03975309 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT03975309 about?

NCT03975309 is a clinical study titled "DHS MIND Metabolomics". The study team will evaluate whether metabolomic signatures of neurocognitive decline trajectories are exacerbated by the presence of type 2 diabetes mellitus (T2D) and whether these signatures contribute in part, to ethnic disparities in cognitive decline between European Americans and African Amer...

What is the current status of trial NCT03975309?

This trial is currently completed. The enrollment target is 417 participants. The study started on 2019-09-09. Estimated completion is 2023-05-23.

What conditions does trial NCT03975309 study?

This clinical trial studies the following conditions: Diabetes.

Who is sponsoring clinical trial NCT03975309?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03975309 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.